Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response

Nikita Vladimirov,Or Perlman

DOI: https://doi.org/10.3390/ijms24043151

2023-08-05

Abstract:Immunotherapy constitutes a paradigm shift in cancer treatment. Its FDA approval for several indications has yielded improved prognosis for cases where traditional therapy has shown limited efficiencey. However, many patients still fail to benefit from this treatment modality, and the exact mechanisms responsible for tumor response are unknown. Noninvasive treatment monitoring is crucial for longitudinal tumor characterization and the early detection of non-responders. While various medical imaging techniques can provide a morphological picture of the lesion and its surrounding tissue, a molecular-oriented imaging approach holds the key to unraveling biological effects that occur much earlier in the immunotherapy timeline. Magnetic resonance imaging (MRI) is a highly versatile imaging modality, where the image contrast can be tailored to emphasize a particular biophysical property of interest using advanced engineering of the imaging pipeline. In this review, recent advances in molecular-MRI based cancer immunotherapy monitoring are described. Next, the presentation of the underlying physics, computational, and biological features are complemented by a critical analysis of the results obtained in preclinical and clinical studies. Finally, emerging artificial intelligence (AI)-based strategies to further distill, quantify, and interpret the image-based molecular MRI information are discussed in terms of perspectives for the future.

Medical Physics

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the monitoring of cancer immunotherapy responses. Specifically, the paper focuses on how to use molecular magnetic resonance imaging (molecular MRI) technology to detect and evaluate the impact of immunotherapy on tumors earlier. Traditional methods such as tissue biopsy or conventional imaging examinations have disadvantages such as invasiveness, sampling limitations, and insensitivity to early biological effects, while molecular MRI can provide non - invasive, high - resolution images for monitoring changes in the tumor microenvironment, the distribution of therapeutic drugs, and the activity of host tissues, thereby achieving early and accurate evaluation of immunotherapy responses.

The paper mentions that although immunotherapy has shown good efficacy in some refractory cancers, not all patients can benefit from it, and currently, very little is known about the factors that determine the treatment outcome in individual patients. Therefore, it is crucial to develop effective monitoring means to identify early treatment responders and non - responders. This will not only help to adjust treatment regimens in a timely manner, reducing unnecessary chemotherapy or radiotherapy, but also improve the design efficiency and success rate of clinical trials.

In addition, the paper also explores the application value of molecular MRI in dealing with pseudo - progression, a phenomenon unique to immunotherapy. Pseudo - progression refers to the situation where the tumor volume temporarily increases at the initial stage of treatment due to immune cell infiltration and other reasons, but may subsequently shrink. This is easily misjudged as ineffective treatment in traditional imaging examinations. Through molecular MRI technology, it is possible to more accurately distinguish between true disease progression and pseudo - progression, providing an important basis for clinical decision - making.